Choreo LLC Buys Shares of 1,047 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Choreo LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, Holdings Channel.com reports. The firm purchased 1,047 shares of the biopharmaceutical company’s stock, valued at approximately $920,000.

Several other hedge funds have also recently modified their holdings of the stock. Accurate Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $229,000. Cambridge Investment Research Advisors Inc. raised its position in Regeneron Pharmaceuticals by 135.8% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 10,126 shares of the biopharmaceutical company’s stock worth $8,333,000 after acquiring an additional 5,832 shares in the last quarter. Tectonic Advisors LLC raised its position in Regeneron Pharmaceuticals by 4.8% in the third quarter. Tectonic Advisors LLC now owns 769 shares of the biopharmaceutical company’s stock worth $633,000 after acquiring an additional 35 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in Regeneron Pharmaceuticals by 0.5% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 8,391 shares of the biopharmaceutical company’s stock valued at $6,905,000 after acquiring an additional 42 shares during the period. Finally, Simon Quick Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 19.2% during the 3rd quarter. Simon Quick Advisors LLC now owns 435 shares of the biopharmaceutical company’s stock worth $358,000 after purchasing an additional 70 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on REGN. TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target for the company. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Barclays lifted their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. Finally, UBS Group upped their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $977.77.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Joseph J. Larosa sold 1,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $950.00, for a total transaction of $950,000.00. Following the completion of the sale, the executive vice president now owns 38,543 shares in the company, valued at approximately $36,615,850. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $950.00, for a total transaction of $950,000.00. Following the transaction, the executive vice president now directly owns 38,543 shares of the company’s stock, valued at $36,615,850. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders have sold a total of 10,095 shares of company stock worth $9,664,476 in the last three months. 8.83% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Stock Up 1.4 %

Shares of REGN opened at $903.48 on Thursday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The company’s fifty day moving average is $944.78 and its two-hundred day moving average is $895.25. The firm has a market cap of $99.17 billion, a PE ratio of 26.00, a price-to-earnings-growth ratio of 2.55 and a beta of 0.17. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same period last year, the company posted $10.96 EPS. The business’s quarterly revenue was up .6% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.